Table 3: Cost, doses and population at risk for universal palivizumab prophylaxis for healthy infants with scenarios A* and B† during the 2009 RSV season

Age; weight, kg	Month; monthly cost per dose per eligible healthy term infant, $
Age; weight, kg	December 2008	January 2009	February 2009	March 2009	April 2009	May 2009
Birth; 3.5	880	880	880	880	880	880
1 mo; 4.3	1069	1069	1069	1069	1069	1069
2 mo; 5.05	1247	1247	1247	1247	1247	1247
3 mo; 5.75	1413	1413	1413	1413	1413	1413
4 mo; 6.45	1579	1579	1579	1579	1579	1579
5 mo; 7.0	1709	1709	1709	1709	1709	1709
6 mo; 7.55	-	1840	1840	1840	1840	1840
7 mo; 8.05	-	-	1958	1958	1958	1958
8 mo; 8.45	-	-	-	2053	2053	2053
9 mo; 8.85	-	-	-	-	2148	2148
10 mo; 9.25	-	-	-	-	-	2243	Sum
Sum scenario A	7897	9737	11 695	13 748	15 896	18 139	77 112
Sum scenario B	7897	7897	7897	7897	7897	7897	47 382

Note: RSV = respiratory syncytial virus.

*Scenario A: Eligible infants are those who would be less than 6 months of age by Jan. 1, 2009 or born before May 31, 2009. Prophylaxis is stopped by May 31, 2009. Annual cost per region = $6423.82 × number of births/year. Monthly doses = number of doses per month x 1/12 × births/year. Annual doses = 51 × 1/12 births/year = 4.25 × births/year. Population at risk = 51/72 × births/year.

†Scenario B: Eligible infants are those who would be less than 6 months of age by Jan. 1, 2009 or born before May 31, 2009. Prophylaxis is stopped by 6 months of age. Model assumes that an equivalent number of infants are born as surpass the age criteria. Annual cost per region = $7897/month × 6/12 births/year = $3947.29 × births. Monthly doses = number of doses per month × 1/12 birth/year = 6/12 × births. Annual doses = 6 × 6/12 births/year. Population at risk = 36/72 × births/year.